menu
    • menu
    [{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Series A Financing","leadProduct":"AVZO-021","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Avenzo Therapeutics \/ New Enterprise Associates","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ New Enterprise Associates"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"AVZO-021","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Avenzo Therapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Avenzo Therapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"VelaVigo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ADC-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Avenzo Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Avenzo Therapeutics \/ Avenzo Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Avenzo Therapeutics \/ Avenzo Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Avenzo Therapeutics

    Menu

    Avenzo Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Avenzo Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Avenzo Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADC-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : VelaVigo

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            VelaVigo Licenses Nectin4/TROP2 Bispecific Antibody-Drug Conjugate from Avenzo

                            Details : Avenzo gains an exclusive option to an exclusive license to develop, manufacture and commercialize a potential first-in-class Nectin4/TROP2 bispecific ADC globally (excluding Greater China).

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 18, 2024

                            Lead Product(s) : ADC-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : VelaVigo

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Avenzo Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Avenzo Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVZO-021,Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Gilead Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Avenzo Partners with Gilead For Breast Cancer Study with AVZO-021

                            Details : The collaboration aims to evaluate AVZO-021, a best-in-class CDK2 inhibitor, in combination with Gilead’s Trodelvy (sacituzumab govitecan), for patients with HR-positive, HER2-negative breast cancer.

                            Brand Name : AVZO-021

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 03, 2024

                            Lead Product(s) : AVZO-021,Sacituzumab Govitecan

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Gilead Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Avenzo Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Avenzo Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AVZO-021,Fulvestrant,Letrozole

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : New Enterprise Associates

                            Deal Size : $150.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Avenzo Therapeutics Announces $150M Oversubscribed Financing for Oncology

                            Details : Proceeds will advance Avenzo’s ARTS-021, a selective CDK2 inhibitor in a Phase 1 study for HR+/HER2- metastatic breast cancer and other advanced solid tumors.

                            Brand Name : ARTS-021

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 26, 2024

                            Lead Product(s) : AVZO-021,Fulvestrant,Letrozole

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : New Enterprise Associates

                            Deal Size : $150.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth